Sisram Medical (HKG:1696) opened a new direct office in Thailand and obtained approval for its Profhilo injection from the Thailand Food and Drug Administration, a Monday filing with the Hong Kong Exchange said.
The company plans to get more approvals from Thailand's regulator, while it starts its direct operations in the region with the injectables.
The cosmeceuticals and medical products company's shares were up nearly 5% on Monday's close.
Price (HKD): $4.04, Change: $+0.18, Percent Change: +4.66%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.